# Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer

> **NCT02311101** · PHASE1 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 18 (actual)

## Conditions studied

- Urinary Bladder Neoplasm

## Interventions

- **DRUG:** Mitomycin C

## Key facts

- **NCT ID:** NCT02311101
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02311101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02311101, "Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02311101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*